SCHEMBL29603717

SCHEMBL29603717

Cc1ccccc1C1=NCc2nnc(C)n2-c2sc3c(c21)C[C@H](C(=O)N1CCOCC1)C3

nearest known ligand 0.87

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 16/20 0.87
CYP3A4 P08684 1/20 0.51
ALOX15 P16050 1/20 0.51
OPRK1 P41145 1/20 0.40
PDE4D Q08499 1/20 0.40
TBXAS1 P24557 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24442169 1.00 PTAFR (0.87) PTAFRCYP3A4ALOX15OPRK1PDE4D
Bepafant SCHEMBL10435458 0.93 PTAFR (1.00) PTAFRCYP3A4ALOX15OPRK1PDE4D
Bepafant SCHEMBL29658830 0.93 PTAFR (1.00) PTAFRCYP3A4ALOX15OPRK1PDE4D
Bepafant SCHEMBL94512 0.93 PTAFR (1.00) PTAFRCYP3A4ALOX15OPRK1PDE4D
SCHEMBL24442268 0.93 PTAFR (0.85) PTAFRCYP3A4ALOX15OPRK1PDE4D
Bepafant SCHEMBL9746762 0.93 PTAFR (1.00) PTAFRCYP3A4ALOX15OPRK1PDE4D
Bepafant SCHEMBL29603620 0.93 PTAFR (1.00) PTAFRCYP3A4ALOX15OPRK1PDE4D
SCHEMBL24442260 0.92 PTAFR (0.84) PTAFRCYP3A4ALOX15OPRK1PDE4D
SCHEMBL24442211 0.92 PTAFR (0.84) PTAFRCYP3A4ALOX15OPRK1PDE4D
SCHEMBL29602692 0.92 PTAFR (0.84) PTAFRCYP3A4ALOX15OPRK1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117624188-A Cyclopentathiofuran carboxamide derivatives as platelet-activating factor receptor antagonists 勃林格殷格翰国际有限公司 2024-03-01 CN disclosed
US-20230355638-A1 Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists BOEHRINGER INGELHEIM INT (DE) 2023-11-09 US disclosed
US-11766443-B2 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-26 US disclosed
EP-4244229-A1 CYCLOPENTATHIOPHENE CARBOXAMIDE DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2023-09-20 EP disclosed
CN-116745300-A Cyclopentathiofuran carboxamide derivatives as platelet-activating factor receptor antagonists 勃林格殷格翰国际有限公司 2023-09-12 CN disclosed
US-20220160725-A1 Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2022-05-26 US disclosed
WO-2022101377-A1 CYCLOPENTATHIOPHENE CARBOXAMIDE DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160725-A1 Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists PTAFR, PDGFRA, F3 PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885
US-11766443-B2 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists PTAFR, PDGFRA, F3 PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885
US-20230355638-A1 Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists PTAFR, PDGFRA, F3 PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.